| Identification | Back Directory | [Name]
EW-7197 Hydrochloride | [CAS]
1352610-25-3 | [Synonyms]
EW-7197 Hydrochloride
TEW-7197 Hydrochloride
Vactosertib Hydrochloride
Vactosertib (EW-7197) Hydrochloride | [Molecular Formula]
C22H19ClFN7 | [MDL Number]
MFCD31619301 | [MOL File]
1352610-25-3.mol | [Molecular Weight]
435.89 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:50.0(Max Conc. mg/mL);114.71(Max Conc. mM)
Water:50.0(Max Conc. mg/mL);114.71(Max Conc. mM) | [form ]
Solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
Vactosertib, also known as TEW-7197 is a potent ALK5 inhibitor. TEW-7197 showed potent in vivo anti-metastatic activity, indicating its potential for use as an anti-cancer therapy. EW-7197 inhibits TGF-β/Smad signaling. EW-7197 abrogates TGF-β1-induced tumor cell migration and invasion. EW-7197 inhibits breast cancer metastasis to the lung.EW-7197 prolongs the life span of BALB/c 4T1 mice via inhibition of EMT. EW-7197 inhibits metastasis and enhances the activity of cytotoxic T lymphocytes (CTLs) in 4T1 orthotopic grafted mic | [Uses]
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect[1][2]. | [in vivo]
EW-7197 treatment ameliorates acquired lymphedema in a mouse tail model by increasing lymphangiogenesis and interstitial flow of the lymphatics by inhibition of the fibrosis. The differences in maximal tail thicknesses between the control and treatment groups were statistically significant from 2 to 4 weeks after surgery. The treatment group showed a greater number of lymphatic vessels at the surgery site than the control group. The treatment group also showed more FITC coverage area at the surgery site._x000D_
_x000D_
Reference: Lymphat Res Biol. 2020 Oct;18(5):433-438. https://pubmed.ncbi.nlm.nih.gov/32105567/ | [target]
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is an ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. | [IC 50]
ALK5: 12.9 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Son JY, et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther. 2014 Jul;13(7):1704-16. DOI:10.1158/1535-7163.MCT-13-0903
[2] Naka K, et al. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci. 2016 Feb;107(2):140-8. DOI:10.1111/cas.12849 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|